Epicrispr Biotechnologies reported that its epigenetic editor EPI-321 increased lean muscle mass in three patients with facioscapulohumeral muscular dystrophy (FSHD) in an ongoing phase 1/2 trial. The Bay Area biotech has treated nine patients so far. Among the three who received the lower dose, lean muscle rose by an average of 0.8 pounds six months after a single IV infusion, ranging from 0.5 to 1.3 pounds per patient. Epicrispr said there were no serious adverse events. The company’s technology silences the Dux4 gene, which drives FSHD, by methylating it through a viral vector-delivered enzyme. CEO Amber Salzman called the early results a “major scientific breakthrough,” and the trial’s principal investigator noted that the gains could indicate biological correction of disease mechanisms. FSHD affects about 870,000 people globally and currently has no approved therapies.
These data, though still early, represent the first public instance of a therapy increasing muscle volume in FSHD, a field where multiple programs have fallen short, including Sanofi’s losmapimod and Roche’s emugrobart. The safety profile and directional efficacy signal set Epicrispr apart in a space where small molecules and antibodies have struggled to show meaningful impact. If verified in later cohorts, the approach could help establish gene silencing as a tangible path for epigenetic disease correction. Still, durability remains the key unknown: whether methylation of Dux4 holds long enough to sustain benefit without repeat dosing. And beyond that, the practical question, will the added muscle translate into real functional improvement as follow-up data arrive?
For deeper coverage of emerging genetic therapies and dosing economics, see ClinicalRx.ai.
